Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are managed.

The screening drive, titled ‘Mission Madhumeha’ (diabetes), was conducted from October 2024 to March 31, 2025, to assess the ...